Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
Jasper Therapeutics has acquired Kira Pharmaceuticals in an all-stock transaction, concurrently closing a $132M private placement to fund the combined company's operations through the second half of 2028. The merger consolidates a pipeline of immunology therapies, including Phase 2/3 ready KP-104 and late-stage briquilimab, while Kira out-licensed two assets (KP-301, KP-402) to Mirador Therapeutics for a $12M upfront payment.
Key figures
- Shares Offered
- 4700000
- Cvr value
- 30000000
- Cash runway
- second half of 2028
- Pipe proceeds
- 132000000
- Mirador upfront
- 12000000
- Conversion ratio
- 61
- Post close shares outstanding
- 653600000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.